(Q35132185)

6 August 2017

1 reference

title

Incorporating the assessment of abuse liability into the drug discovery and development process (English)

1 reference

6 August 2017

1 reference

Robert S Mansbach

1

1 reference

6 August 2017

Douglas E Feltner

series ordinal

2

1 reference

6 August 2017

Lisa H Gold

series ordinal

3

1 reference

6 August 2017

Sidney H Schnoll

series ordinal

4

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Drug and Alcohol Dependence

6 August 2017

published in

1 reference

6 August 2017

volume

70

1 reference

6 August 2017

issue

3 Suppl

1 reference

6 August 2017

page(s)

S73-85

1 reference

Experimental analysis of the ?happy hour?: Effects of purchase price on alcohol consumption

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Conditioned place preference: what does it add to our preclinical understanding of drug reward?

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

The intravenous self-administration of antihistamines by rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Effects of response requirement upon human sedative self-administration and drug-seeking behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Abuse potential of dronabinol (Marinol).

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Drug discrimination in neurobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Psychomotor stimulant addiction: a neural systems perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Methadone: a review of its pharmacokinetic/pharmacodynamic properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Suppression of ethanol self-administration in alcoholics by contingent time-out from social interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Gender effects in pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Pain management, controlled substances, and state medical board policy: a decade of change

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Comorbidity between patterns of substance use dependence and psychiatric syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Abuse liability assessment of neuroprotectants

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Tramadol post-marketing surveillance in health care professionals

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Effects of varying the "openness" of an economy on responding for cigarettes.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

1 reference

7 January 2021

Psychotomimesis mediated by kappa opiate receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Addiction Rare in Patients Treated with Narcotics

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Abuse of pentazocine-naloxone combination

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Co-occurring mental and substance use disorders: promising approaches and research issues

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Aspects of tolerability of centrally acting antihypertensive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Opioid pseudoaddiction--an iatrogenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

Evaluation of the abuse liability of aminorex.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900100-5

7 January 2021

10.1016/S0376-8716(03)00100-5

Identifiers

DOI

1 reference

6 August 2017

1 reference